Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer

Journal of Innate Immunity

Volumn 7, Issue 3, 2015, Pages 302-314

  Rogers, Geoffrey L ^a   Suzuki, Masataka ^b   Zolotukhin, Irene ^a   Markusic, David M ^a   Morel, Laurence M ^a   Lee, Brendan ^c,d   Ertl, Hildegund C J ^e   Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e WISTAR INSTITUTE   (United States)

Author keywords

Adeno associated viral vectors; Antibody; CD8+ T cell; Gene therapy; Immune responses; Innate immunity; MyD88; TLR9

Indexed keywords

ADENO ASSOCIATED VIRAL VECTOR; ADENOVIRUS VECTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MYD88 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IN VIVO GENE TRANSFER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; ANIMAL; B LYMPHOCYTE; DEPENDOPARVOVIRUS; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; IMMUNOGLOBULIN G; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; TOLL-LIKE RECEPTOR 9; TRANSDUCTION, GENETIC;

EID: 84929026406     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000369273     Document Type: Article

References (41)

1. Mingozzi F, High KA: Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12: 341-355.
2. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA: Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000; 1: 225-235.
3. Mingozzi F, High KA: Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013; 122: 23-36.
4. Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW: Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 2009; 17: 1733-1742.
5. Hoffman BE, Martino AT, Sack BK, Cao O, Liao G, Terhorst C, Herzog RW: Nonredundant roles of IL-10 and TGF in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol Ther 2011; 19: 1263-1272.
6. Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, Loduca PA, High KA, Herzog RW: Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 2013; 5: 1698-1709.
7. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC, High KA: Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13: 1281-1291.
8. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW: Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 2005; 105: 4226-4234.
9. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW: Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005; 12: 1453-1464.
10. Masat E, Pavani G, Mingozzi F: Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med 2013; 15: 379-389.
11. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
12. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM: Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
13. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW: Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013; 121: 2224-2233.
14. Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW: Innate immune responses to AAV vectors. Front Microbiol 2011; 2: 194.
15. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA: Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-4590.
16. Zhu J, Huang X, Yang Y: The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009; 119: 2388-2398.
17. Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, Wilson JM: CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 2013; 123: 2994-3001.
18. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW: The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011; 117: 6459-6468.
19. Wu T, Topfer K, Lin SW, Li H, Bian A, Zhou XY, High KA, Ertl HC: Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther 2012; 20: 572-579.
20. Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW: Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med 2014; 12: 25.
21. Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, Gillen S, Kleeff J, Stabenow D, Odenthal M, Knolle P, Hallek M, Protzer U, Buning H: Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012; 55: 287-297.
22. Sudres M, Cire S, Vasseur V, Brault L, Da Rocha S, Boisgerault F, Le Bec C, Gross DA, Blouin V, Ryffel B, Galy A: MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther 2012; 20: 1571-1581.
23. Suzuki M, Bertin TK, Rogers GL, Cela RG, Zolotukhin I, Palmer DJ, Ng P, Herzog RW, Lee B: Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther 2013; 21: 796-805.
24. Hong EH, Chang SY, Lee BR, Kim YS, Lee JM, Kang CY, Kweon MN, Ko HJ: Blockade of MyD88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells. Int J Cancer 2013; 132: 2839-2848.
25. Sarkar D, Biswas M, Liao G, Seay HR, Perrin GQ, Markusic DM, Hoffman BE, Brusko TM, Terhorst C, Herzog RW: Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia. Mol Ther Methods Clin Dev 2014; 1: 14030.
26. Kim SJ, Caton M, Wang C, Khalil M, Zhou ZJ, Hardin J, Diamond B: Increased IL-12 inhibits B cells differentiation to germinal center cells and promotes differentiation to shortlived plasmablasts. J Exp Med 2008; 205: 2437-2448.
27. Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, Cao O, Herzog RW: Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 2007; 18: 603-613.
28. Barr TA, Brown S, Mastroeni P, Gray D: B cell intrinsic MyD88 signals drive IFN production from T cells and control switching to Ig-G2c. J Immunol 2009; 183: 1005-1012.
29. Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL: Selective utilization of tolllike receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 2011; 34: 375-384.
30. Bhat N, Fitzgerald KA: Recognition of cytosolic DNA by cGAS and other STING-dependent sensors. Eur J Immunol 2014; 44: 634-640.
31. Homann D, Tishon A, Berger DP, Weigle WO, von Herrath MG, Oldstone MB: Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J Virol 1998; 72: 9208-9216.
32. Wang X, Moghimi B, Zolotukhin I, Morel LM, Cao O, Herzog RW: Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Mol Ther 2014; 22: 1139-1150.
33. McIntosh JH, Cochrane M, Cobbold S, Waldmann H, Nathwani SA, Davidoff AM, Nathwani AC: Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther 2012; 19: 78-85.
34. Gaddis DE, Michalek SM, Katz J: TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B. J Immunol 2011; 186: 5772-5783.
35. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A: Integration of B cell responses through toll-like receptors and antigen receptors. Nat Rev Immunol 2012; 12: 282-294.
36. Jankovic D, Kullberg MC, Hieny S, Caspar P, Collazo CM, Sher A: In the absence of IL-12, CD4+ T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10-/-setting. Immunity 2002; 16: 429-439.
37. Chakarov S, Fazilleau N: Monocyte-derived dendritic cells promote T follicular helper cell differentiation. EMBO Mol Med 2014; 6: 590-603.
38. Browne EP: Regulation of B-cell responses by toll-like receptors. Immunology 2012; 136: 370-379.
39. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, Shan M, Xiong H, Bussel JB, Chiu A, Puel A, Reichenbach J, Marodi L, Doffinger R, Vasconcelos J, Issekutz A, Krause J, Davies G, Li X, Grimbacher B, Plebani A, Meffre E, Picard C, Cunningham-Rundles C, Casanova JL, Cerutti A: The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010; 11: 836-845.
40. Almejun MB, Cols M, Zelazko M, Oleastro M, Cerutti A, Oppezzo P, Cunningham-Rundles C, Danielian S: Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. Eur J Immunol 2013; 43: 805-814.
41. Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A: Activation of the NF-B pathway by adenoassociated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci U S A 2011; 108: 3743-3748.